Results 211 to 220 of about 172,321 (305)

Lead‐Associated Superior Vena Cava Syndrome: Diagnostic Delay and the Role of Invasive Pressure Measurements

open access: yesPacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Superior vena cava (SVC) syndrome is an uncommon complication of transvenous cardiac device leads. Diagnosis may be challenging due to gradually developing and nonspecific symptoms. Furthermore, anatomical imaging does not always reflect the hemodynamic significance of venous stenosis.
Fenna Daniëls   +5 more
wiley   +1 more source

Transjugular Left Atrial Appendage Occlusion in a Patient With Anomalous Inferior Vena Cava. [PDF]

open access: yesJACC Case Rep
Yap RL   +9 more
europepmc   +1 more source

Safety of Pulsed Field Ablation: Established Evidence, Emerging Risks, and Knowledge Gaps

open access: yesPacing and Clinical Electrophysiology, EarlyView.
Overview of the safety profile of pulsed field ablation (PFA), highlighting established safety advantages, procedure‐related complications, electroporation‐specific effects, and key areas of ongoing uncertainty, particularly for ventricular applications.
Dakota de Cecco   +3 more
wiley   +1 more source

Atrial Fibrillation Ablation Across an Inferior Vena Cava Filter. [PDF]

open access: yesCureus
Beladel W   +4 more
europepmc   +1 more source

Understanding exosomes in facial esthetics and skin aging

open access: yesPeriodontology 2000, EarlyView.
Abstract Background Skin aging is a multifactorial process mediated by intrinsic (genetic and metabolic) and extrinsic (environmental) factors leading to functional and structural deterioration, including wrinkles, loss of collagen and elastin, as well as various pigmentation disorders.
Richard J. Miron   +3 more
wiley   +1 more source

Inferior Vena Cava Filter Fracture Presenting as Deep Vein Thrombosis. [PDF]

open access: yesClin Case Rep
Shigemoto K   +6 more
europepmc   +1 more source

Combination of Hypofractionated Radiation Therapy and Gilvetmab for the Treatment of Cutaneous or Subcutaneous Mast Cell Tumours in Dogs

open access: yesVeterinary and Comparative Oncology, EarlyView.
ABSTRACT Gilvetmab is a caninised monoclonal antibody against canine PD‐1. Concurrent or sequential administration of anti‐PD‐1 antibodies and radiation therapy (RT) improves survival time in various species. Eighteen dogs with mast cell tumours (MCTs) were prospectively treated with 24 Gy of RT over Days 0, 7 and 21 and gilvetmab every 2 weeks ...
Tiffany W. Martin   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy